

Hospital Outpatient Claim Example



Black = Required Blue = Situational/Required, if applicable Forest Lake Hospital STATEMENT COVERS PERIOD FROM THROUGH 123 Vista Ridge Road 5 FED. TAX NO. 01/07/22 01/07/22 Bend OR 8 PATIENT NAME 9 PATIENT ADDRESS ^a 123 Mountain Drive John Smith Bend ADMISSION 13 HR 14 TYPE 15 SRC 10 BIRTHDATE 1/1/57 42 REV. CD. 43 DESCRIPTION 44 HCPCS / RATE / HIPPS CODE 47 TOTAL CHARGES 48 NON-COVERED CH/ 01/07/22 XXXX 0360 Intraosseous des lumb/sacrum 64628 XXXX 0360 Intraosseous destruct add'l 64629 01/07/22 Intracept Device(Probe & Access) C1889 01/07/22 XXXX 0278 Cost of Intracept device plus markup (consider the cost of additional level access kit(s) if treating more than 2 VBs.) 64628 – Thermal destruction of intraosseous basivertebral nerve, inclusive of all imaging guidance; first two vertebral bodies, lumbar or sacral. 64629 - Thermal destruction of intraosseous basivertebral nerve, inclusive of all imaging guidance; each additional vertebral bodies, lumbar or sacral. OF **PAGE CREATION DATE TOTALS** 51 HEALTH PLAN ID 54 PRIOR PAYMENTS 55 EST. AMOUNT DUE 56 NPI Great Health Insurance Co. PPO73925 57 OTHER PRV ID 59 P.REL 60 INSURED'S UNIQUE ID 58 INSURED'S NAME 61 GROUP NAME 62 INSURANCE GROUP NO. KFJ123456789 654321 Jones, Macie 63 TREATMENT AUTHORIZATION CODES A123456789 M54.51 OTHER PROCEDUR 76 ATTENDING FIRST 77 OPERATING

Indications for Use: The Intracept™Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change). Contraindications - Use of the Intracept Intraosseous Nerve Ablation System is contraindicated in: Patients with severe cardiac or pulmonary compromise, patients with active implantable pulse generators (e.g. pacemakers, defibrillators), patients where the targeted ablation zone is < 10 mm away from a sensitive structure not intended to be ablated, including the vertebral foramen (spinal canal), patients with active systemic infection or local infection in the area to be treated, patients who are pregnant, and/or skeletally immature patients (generally ≤ 18 years of age). Refer to the Instructions for Use provided with the Intracept Procedure or w ww.relievant.com/intracept/ for potential adverse effects, warnings, and precautions prior to using this product.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Disclaimer: Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services, and to submit appropriate codes, charges, and modifiers for services rendered. It is also always the provider's responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters. Boston Scientific does not promote the use of its products outside their FDA- approved label. Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding, or site of service requirements. All trademarks are the property of their respective owners. The coding options listed within this guide are com monly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options. This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included solely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for se

 $NM-2237307-AA\ Copyright\ @\ 2025\ by\ Boston\ Scientific\ Corporation\ or\ its\ affiliates.\ All\ rights\ reserved.$